Calcific Uremic Arteriolopathy, report of a case treated with Sodium Thiosulfate
PDF (Español (España))


Sodium thiosulfate
Chronic kidney disease

How to Cite

Herrera Muñoz S, Buitrago Villa CA, Serna Toro MJ, Restrepo Valencia CA. Calcific Uremic Arteriolopathy, report of a case treated with Sodium Thiosulfate. Rev. Colomb. Nefrol. [Internet]. 2015 Mar. 20 [cited 2023 Apr. 1];2(1):63-70. Available from:


We describe a case of calcific uremic arteriolopathyinitially associated with skin lesions within the context of a patient with chronic kidney disease on automated peritoneal dialysis therapy. Among the most relevant findings, the patient hadhyperphosphatemia, normocalcemia and severe hyperparathyroidism without nodular hyperplasia. Clinical improvement with multimodal management of enhancement in dialysis therapy and intravenous sodium thiosulfate is highlighted. Calciphylaxis is a disorder that has a high morbidity and mortality, secondary to sepsis. It occurs more frequently in patients with chronic renal failure who are on hemodialysis. It is characterized by systemic medial calcification of the arterioles, triggering ischemia and subcutaneous necrosis of skin and soft tissues. Histopathological evaluation helps to confirm the diagnosis.
PDF (Español (España))


1. AdroguéHJ, Frazier MR, Zeluff B, Suki WN.Systemic calciphylaxis revisited. Am J Nephrol. 1981;1:177-83.

2. Kent RB 3rd, Lyerly RT. Systemic calciphylaxis. South Med J. 1994;87:278-281.

3. Janigan DT, Hirsch DJ, Klassen GA, MacDonald AS. Calcified subcutaneous arterioles with infarcts of the subcutis and skin (“calciphylaxis”) in chronic renal failure. Am J Kidney Dis. 2000;35:588-597.

4. Nigwekar SU, Wolf M, Sterns RH, Hix JK.Calciphylaxis from nonuremic causes: a systematic review.Clin J Am Soc- Nephrol. 2008;3:1139-1143.

5. Angelis M, Wong LL, Myers SA, Wong LM.Calciphylaxis in patients on hemodialysis: a prevalence study.Surgery. 1997;122:1083-1090.

6. Mazhar AR, Johnson RJ, Gillen D, Stivelman JC, Ryan MJ, Davis CL, Stehman-Breen CO.Risk factors and mortality associated with calciphylaxis in end-stage renal disease.Kidney Int. 2001;60:324-332.

7. Bleyer AJ, Choi M, Igwemezie B, de la Torre E, White WL.A case control study of proximal calciphylaxis.Am J KidneyDis. 1998;32:376.

8. Fine A, Zacharias J.Calciphylaxis is usually non-ulcerating: risk factors, outcome and therapy.KidneyInt. 2002;61:2210-2217.

9. Weenig RH, Sewell LD, Davis MD, McCarthy JT, Pittelkow MR. Calciphylaxis: natural history, risk factor analysis, and outcome.J Am AcadDermatol. 2007;56:569-579.

10. Musso CG, Enz P, Vidal F, Gelman R, Giuseppe LD, Bevione P, Garfi L, Galimberti R, Algranati L. Oral sodium Thiosulfate solution as a secondary preventive treatment for calciphylaxis in dialysis patients. Saudi J KidneyDis- Transplant 2008;19:820-821.

11. Zitt E, Konig M, Vychytil A, Auinger M, Wallner M, Lingenhel G, Schilcher G, Rudnicki M, SalmhoferHLhotta K. Use of sodium hiosulphate in a multi- interventional setting for the treatment of calciphylaxis in dialysis patients. Nephrol Dial Transplant. 2013;28:1232-1240.

12. Nigwekar SU, Brunelli SM, Meade D, Wang W, Hymes J, Lacson EJr. Sodium thiosulfate therapy for calcific uremic arteriolopathy. Clin J Am SocNephrol. 2013;8:1162-1170.

13. Adirekkiat S, Sumethkul V, Ingsathit A, Domrongkitchaiporn S, Phakdeekitcharoen B, Kantachuvesiri S, Kitiyakara C, Klyprayong P, Disthabanchong S. Sodium thiosulfate delays the progression of coronary artery calcification in haemodialysis patients. Nephrol Dial Transplant. 2010;25:1923-1929.
No national or foreign publication may partially or totally reproduce or translate Revista Colombiana de Nefrología articles or abstracts without prior written permission from the journal’s Editorial Board.




Download data is not yet available.